Eli Lilly Neutralizing Antibodies: Breakthrough for COVID-19 Treatment?

September 18, 2020

Eli Lilly stated LY-CoV555 was “well tolerated” without the observation of any drug-related serious events. And that adverse events were similar to placebo. However, the exact incidence of milder drug reactions which could affect patient acceptance were not given.

Visiting Hours: Time to Re-evaluate Restrictions Caused by COVID

September 17, 2020

Most hospitals have implemented stringent visitor restrictions that don’t allow anyone to visit, even during end of life. While an understandable public health and infection prevention measure, it has generated some concern.

Taking Aim at Antibiotic-Resistant Bacteria During COVID

September 16, 2020

Patients afflicted with COVID-19 have an increased susceptibility to antibiotic resistant infections both from prolonged hospitalizations and the use of immunocompromising agents such as dexamethasone.